Please check your internet connection and try again.
## Piperacillin/Tazobactam (Zosyn)
### Overview
Piperacillin/tazobactam is a combination of an extended-spectrum penicillin antibiotic and a beta-lactamase inhibitor. It is bactericidal and has a broad spectrum of activity against many Gram-positive, Gram-negative, and anaerobic bacteria.
### Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin structure infections
* Community-acquired pneumonia
* Hospital-acquired pneumonia (including ventilator-associated pneumonia)
* Febrile neutropenia (empiric treatment)
### Adult Dosing
* **Standard Dose:** 3.375 g (piperacillin 3 g/tazobactam 0.375 g) intravenously every 6 hours.
* **Higher Dose (for severe infections or specific pathogens):** 4.5 g (piperacillin 4 g/tazobactam 0.5 g) intravenously every 6 or 8 hours.
* **Duration:** Typically 7 to 14 days, depending on the indication and clinical response. Specific protocols may dictate duration.
### Pediatric Dosing
Dosing varies significantly by indication and weight. Consult specific pediatric guidelines or protocols. A common example for complicated intra-abdominal infections in patients > 12 years old and weighing > 40 kg is 3.375 g IV every 6 hours. For younger children, doses are often calculated based on piperacillin weight-based dosing (e.g., 100 mg/kg/dose of piperacillin component) every 6-8 hours, with the tazobactam component dosed at 12.5 mg/kg/dose.
### Dose Adjustments
* **Renal Impairment:**
* CrCl > 40 mL/min: No dose adjustment needed.
* CrCl 20-40 mL/min: Administer 2.25 g (piperacillin 2 g/tazobactam 0.25 g) every 6 hours.
* CrCl < 20 mL/min: Administer 2.25 g (piperacillin 2 g/tazobactam 0.25 g) every 8 hours.
* Consider intermittent hemodialysis: Administer 2.25 g (piperacillin 2 g/tazobactam 0.25 g) every 8 hours, with an additional 0.75 g dose after each dialysis session.
* **Hepatic Impairment:** No specific dose adjustment recommended, but monitor liver function.
### Contraindications
* Hypersensitivity to piperacillin, tazobactam, other penicillins, or cephalosporins.
* History of cholestatic jaundice or hepatic dysfunction associated with piperacillin/tazobactam therapy.
### Adverse Effects
* **Common:** Diarrhea, rash, nausea, vomiting, headache, insomnia, eosinophilia, elevated liver enzymes (AST/ALT).
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), Stevens-Johnson syndrome/toxic epidermal necrolysis, seizures (especially with high doses or renal impairment), neutropenia, thrombocytopenia, interstitial nephritis, liver injury.
### Key Drug Interactions
* **Aminoglycosides:** Potential for antagonism against *Pseudomonas aeruginosa* when used together. However, synergistic activity may occur in some severe infections; consult local guidelines.
* **Probenecid:** May increase and prolong piperacillin/tazobactam serum levels.
* **Warfarin:** May decrease the effect of warfarin; monitor INR closely.
* **Neuromuscular blocking agents:** May prolong the neuromuscular blockade.
### Monitoring
* Renal and hepatic function.
* Electrolytes.
* Complete blood count (CBC), especially during prolonged therapy, for potential hematologic changes (neutropenia, thrombocytopenia).
* Signs and symptoms of hypersensitivity reactions.
* Signs and symptoms of *Clostridioides difficile*-associated diarrhea.
* Clinical response to therapy.
### Clinical Pearls
* Piperacillin/tazobactam can be administered as a continuous infusion, which may achieve higher drug concentrations and reduce the risk of toxicity in critically ill patients. Specific protocols for continuous infusion dosing should be followed.
* Reconstituted solutions are generally stable for 24 hours at room temperature or 48 hours refrigerated. Check manufacturer's specific recommendations.
* The maximum recommended daily dose should not be exceeded.
---
**Disclaimer:** This information is intended for healthcare professionals and should not be considered a substitute for professional medical advice. Always consult the current prescribing information, institutional protocols, and consider individual patient factors before initiating or modifying drug therapy.
